Laddar...
Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated Tumours
Overactivation of the mitogen-activated protein kinase (MAPK) pathway is an important driver of many human cancers. First line, FDA-approved therapies targeting MAPK signalling, which include BRAF and MEK inhibitors, have variable success across cancers, and a significant number of patients quickly...
Sparad:
| I publikationen: | J Oncol |
|---|---|
| Huvudupphovsmän: | , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Hindawi
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7199609/ https://ncbi.nlm.nih.gov/pubmed/32411231 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/1079827 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|